Clinical trials: Myelodysplastic Syndromes (MDS)
Hematologic Malignancies, Myelogenous Leukemia
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation
The purpose of this study is to evaluate the ability of sirolimus to prevent graft versus host disease (GVHD) in patients following stem cell transplant from a related donor.
- Conditions
- Hematologic Malignancies, Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00144703
- Testing
- Sirolimus, Tacrolimus
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Dana-Farber Cancer Institute
Graft Versus Host Disease, Leukemia
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's…
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00608517
- Testing
- anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder
RATIONALE: Combining antithymocyte globulin with combination chemotherapy before donor peripheral stem cell transplantation may reduce the chance of developing graft-versus-host disease following transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00054340
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Myeloid Leukemia, Myelodysplastic Syndrome
Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)
Efficacy and safety of 5-Azacytidin in the treatment of the haematological relapse in patients suffering from acute myeloid leukaemia or myelodysplastic syndrome with falling CD34-chimerism after hematopoietic stem cell…
- Trial name
- NCT00422890
- Testing
- 5-Azacytidin
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Technische Universität Dresden
Leukemia, Myelocytic, Acute
Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)
The study is designed as a Phase III, multicenter trial comparing outcomes after allogeneic hematopoietic stem cell transplantation (HCT) for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) between patients…
- Trial name
- NCT01339910
- Testing
- Fludarabine and Busulfan, Fludarabine and Melphalan, Busulfan and Fludarabine
- Where
- 32 sites in United States
- Volunteers
- 272 people
- Sponsor
- Medical College of Wisconsin
Leukemia, Myelodysplastic Syndromes
Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with donor bone marrow transplantation may allow the doctor to give higher doses of…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00004896
- Testing
- busulfan, cyclophosphamide, allogeneic bone marrow transplantation
- Where
- United States
- Sponsor
- Northwestern University
Myelodysplastic Syndromes
Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent
Myelodysplastic syndrome (MDS) is widely recognized as a clonal hematopoietic stem cell disorder. Decitabine has been approved for the treatment of all subtypes of myelodysplastic syndrome (MDS).
- Trial name
- NCT03045510
- Testing
- decitabine
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Shandong University
Thrombocytopenia, Purpura, Thrombocytopenic
Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
It is a translational research study with mechanistical objectives and including biological samples of patients with thrombocytopenia
- Conditions
- Thrombocytopenia, Purpura, Thrombocytopenic, Myelodysplastic Syndromes
- Trial name
- ICTUS (NCT04003220)
- Testing
- blood sample, Bone marrow sample
- Where
- 4 sites in France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Hematologic Malignancy
Pilot Study of Multi-Modality Imaging in Patients With Hematologic Malignancies
This is a pilot sub-study of patients receiving myeloablative transplant using total body irradiation (TBI) or total marrow irradiation (TMI) in their preparative regimen.
- Trial name
- NCT02042924
- Testing
- FLT PET/CT, MRI
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
MDS
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
The goal of this clinical trial is to learn about the safety and effectiveness of the combination drug Tetrahydrouridine (THU) and decitabine (DEC) to treat patients with relapsed or refractory myelodysplastic syndrome.
- Trial name
- NCT07006025
- Testing
- Decitabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Treebough Therapies
Myelodysplastic Syndrome
Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients
This is an open-label study designed to evaluate the safety and efficacy of the selective inhibitor of nuclear export (SINE) compound, Selinexor given orally to patients with transfusion-dependent, EPO-refractory lower-risk MDS…
- Trial name
- SIER (NCT02431351)
- Testing
- Selinexor
- Sponsor
- Karyopharm Therapeutics Inc
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS
This is a phase 1 study of investigational drug CFI-400945 in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT03187288
- Testing
- CFI-400945 Fumarate
- Where
- 2 sites in Canada
- Volunteers
- 13 people
- Sponsor
- University Health Network, Toronto
Hematologic Malignancies, Acute Myeloid Leukemia
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
The purpose of this study is to determine the efficacy and safety of transplanting StemEx® in patients with certain hematological malignancies.
- Conditions
- Hematologic Malignancies, Acute Myeloid Leukemia, Lymphoid Leukemia, Chronic Myeloid Leukemia
- Trial name
- ExCell (NCT00469729)
- Testing
- StemEx®
- Where
- 30 sites in United States, Hungary and 3 more
- Volunteers
- 101 people
- Sponsor
- Gamida Cell -Teva Joint Venture Ltd.
Leukemia, Myelodysplasia
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
This is an open label, non-randomized, multicenter, pilot, dose expansion study of low dose post-transplant cyclophosphamide (25 mg/kg on Days +3 and +4)/tacrolimus/ruxolitinib in the setting of myeloablative conditioning (MAC)…
- Conditions
- Leukemia, Myelodysplasia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT07249346
- Testing
- Ruxolitinib, Myeloablative conditioning regimen, Hematopoietic Stem Cell Transplantation
- Where
- 3 sites in United States
- Volunteers
- 124 people
- Sponsor
- Hannah Choe, MD
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
This phase I trial is studying the side effects and best dose of SJG-136 in treating patients with relapsed or refractory acute leukemia, myelodysplastic syndromes, blastic phase chronic myelogenous leukemia, or chronic…
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Trial name
- NCT00301769
- Testing
- SJG-136
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome
Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome
This phase II trial studies the effect of venetoclax and azacitidine in treating patients with therapy related or secondary myelodysplastic syndrome.
- Trial name
- NCT05379166
- Testing
- Azacitidine, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Uma Borate
Acute Leukemia, Myelodysplastic Syndrome
ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory AML And Advanced MDS
Acute myeloid leukemia (AML) is a rapidly fatal malignancy of the bone marrow. It can be treated with chemotherapy alone, in some cases, but in the majority of cases, the only treatment that can cure the disease is an allogeneic…
- Trial name
- ED-TBI (NCT01709396)
- Testing
- ED-TBI
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Ottawa Hospital Research Institute
Lymphoid Leukemia, Myeloid Leukemia
Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients
This phase 2 trial studies the effect of intravenous (IV) vitamin C repletion after myeloablative allogeneic stem cell transplant.
- Conditions
- Lymphoid Leukemia, Myeloid Leukemia, Monocytic Leukemia, Myelodysplasia
- Trial name
- NCT03613727
- Testing
- Intravenous (IV) and oral Vitamin C
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Virginia Commonwealth University
Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
This phase I/II trial studies the side effects and how well cladribine, idarubicin, cytarabine, and quizartinib work in treating patients with acute myeloid leukemia or high-risk myelodysplastic syndrome that is newly diagnosed…
- Conditions
- Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome, Recurrent Acute Biphenotypic Leukemia
- Trial name
- NCT04047641
- Testing
- Cladribine, Cytarabine, Idarubicin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lymphoma
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia
RATIONALE: Bone marrow and peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00002718
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.